Expert Care, Close To Home.
APU Direct
320.259.1411
888.559.1411
Overactive Bladder
- Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy and Safety of XXX in Comparison to Tolterodine ER in Patients with Overactive Bladder
- Placebo Controlled Randomized, 12-Week, Dose-Ranging, Double-Blind Study Versus Placebo using Tolterodine as a Study Calibrator, to Evaluate Efficacy and Safety of XXX in Women with Overactive Bladder Including Urge Urinary Incontinence
- Double-blind, multi-center, international, randomized, placebo-controlled study of safety and efficacy of Trospium chloride 60mg modified release capsules vs. placebo, once daily, for 12 weeks followed by a 9-month, open-label treatment phase in patients with overactive bladder
- Open label, parallel-group, multi-center study to evaluate the efficacy, safety and tolerability of Enablex alone or in combination with behavioral modification program for symptoms of overactive bladder
- Phase II, 12-week, randomized, double-blind multi-center study to evaluate the efficacy of darifenacin vs. placebo
- A phase four, multi-center, naturalistic, open-label, observational study, over 12 weeks of patients initiating a medication for overactive bladder
